Michael Dee, MD
Internal Medicine · Nampa, IDNPI 1053302182
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $784 and has fallen 64.6% since, to $278 in 2025. Among internal medicine clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$443
- Pfizer$415
- AstraZeneca$261
- Boehringer Ingelheim$239
- Novartis$148
- Johnson & Johnson$128
- plus $847 from 24 others
What the payments were for
- Food & beverage$2,481100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $443 |
| Pfizer | 30 | $415 |
| AstraZeneca | 17 | $261 |
| Boehringer Ingelheim | 15 | $239 |
| Novartis | 8 | $148 |
| Johnson & Johnson | 9 | $128 |
| E.r. Squibb & Sons, L.L.C. | 9 | $123 |
| Amgen | 5 | $79 |
| GSK | 4 | $64 |
| Astellas Pharma US Inc | 4 | $56 |
| AbbVie(2 entities) | 3 | $53 |
| Sanofi-aventis U.S. LLC | 4 | $52 |
| Dexcom, Inc. | 3 | $42 |
| Exact Sciences | 2 | $38 |
| Abbott | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $28 |
| Orthofix Medical, Inc. | 2 | $27 |
| Merck | 2 | $24 |
| Mylan Specialty L.p. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Gilead | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Medtronic | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
How this compares
$2,481 in reported general payments places this provider in the 90th percentile of 289 internal medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 255 | $226,917 |
| FarxigaDapagliflozin Propanediol | 162 | $113,752 |
| OzempicSemaglutide | 75 | $71,717 |
| JardianceEmpagliflozin | 72 | $41,393 |
| MyrbetriqMirabegron | 50 | $36,207 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $25,588 |
| XareltoRivaroxaban | 26 | $24,949 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $22,661 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $21,481 |
| TrulicityDulaglutide | 20 | $20,570 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $20,165 |
| JanuviaSitagliptin Phosphate | 17 | $13,488 |
| MounjaroTirzepatide | 13 | $13,192 |
| Gabapentin | 428 | $9,238 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 272 | $7,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $415 | $226,917255 claims |
| AstraZenecaFarxiga | $261 | $113,752162 claims |
| Novo NordiskOzempic | $443 | $71,71775 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $239 | $45,47986 claims |
| Astellas Pharma US IncMyrbetriq | $56 | $36,20750 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $28 | $33,76333 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $64 | $31,04743 claims |
| Johnson & JohnsonXarelto | $128 | $24,94926 claims |
| MerckJanuvia | $24 | $13,48817 claims |
| Sanofi-aventis U.S. LLCAmbien | $52 | $7,40912 claims |
| AbbVieSynthroid | $53 | $2,51444 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 289 internal medicine providers in Idaho.
Other internal medicine in Nampa
- Sarah BarkerNampa$5K
- John SadajNampa$5K
- Stanley StringamNampa$4K
- Ryan WilliamsNampa$492
- Sherwin D'souzaPocatello$543K
- Diana DumitrascuEagle$143K
- Huiling QiBoise$62K
- Aditya SinghPocatello$37K
- Carolyn BridgesBoise$27K
- Susan WachterIdaho Falls$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.